The Impact of Osmotic Release Oral Delivery System Methylphenidate (OROS MPH) Upon Family of Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)

• Sponsor: Johnson & Johnson Taiwan Ltd (Industry)
• Overall Status: Completed
• CT.gov ID: NCT00758160
• Collaborator: (none)
• Enrollment: 296
• Arm: 1
• Duration (Months): 3

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate whether familial relationships and psychological status of participants or caregivers as well as Attention Deficit Hyperactivity Disorder (ADHD) symptoms of participants can be improved by switching from Immediate-release Methylphenidate (IR-MPH) to Osmotic Release Oral Delivery System Methylphenidate (OROS-MPH).

Condition or Disease	Intervention/Treatment	Phase
Attention Deficit Disorder With Hyperactivity	Drug: OROS Methylphenidate	Phase 4

Detailed Description

This is a prospective (study following participants forward in time), single-arm, open-label (all people know the identity of the intervention), 8-week, multi-centric (conducted in more than 1 center) study. OROS-MPH will be administered orally for 2 months at doses of 18, 36, or 54 milligram (mg) to replace IR-MPH. Clinicians will adjust the dose of each participant according to participant's clinical responses and/or side effects. During the study period, participants will be assessed on Week 2, 4, and 8. Efficacy will be evaluated primarily based on change from baseline in Chinese version of the 26-item Swanson, Nolan and Pelham-Fourth Edition (SNAP-IV) rating scale assessed by parents and Chinese Health Questionnaire (CHQ). Safety will be monitored throughout the study.

Study Design

• Study Type: Interventional
• Actual Enrollment: 296 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: From Immediate-release MPH to OROS MPH: The Impact Upon Family of Children and Adolescents With ADHD
• Study Start Date: Mar 1, 2008
• Actual Primary Completion Date: Jun 1, 2008
• Actual Study Completion Date: Jun 1, 2008

Arms and Interventions

Arm	Intervention/Treatment
Experimental: OROS methylphenidate Participants willl receive Osmotic Release Oral Delivery System (OROS) methylphenidate (MPH) 18 milligram (mg), 36 mg or 54 mg once daily for 8 weeks. Dose will be adjusted for each participant based on clinical responses and/or side effects.	Drug: OROS Methylphenidate; Participants will receive Osmotic Release Oral Delivery System (OROS) methylphenidate (MPH) 18 milligram (mg), 36 mg or 54 mg once daily for 8 weeks. Dose will be adjusted for each participant based on clinical responses and/or side effects.

Outcome Measures

Primary Outcome Measures

1. Mean Change From Baseline in Swanson, Nolan and Pelham-Fourth Edition (SNAP-IV) Rating Scale (Parents) Score at Week 2 [Baseline and Week 2]

   Parents were asked to assess their children on a 26-item Chinese SNAP-IV questionnaire consisting of inattention (items 1-9; subscore range 0-27), hyperactivity (items 10-18; subscore range 0-27) and oppositional (19-26, subscore range 0-24) subscales used to assess the qualitative judgments in Attention Deficit Hyperactivity Disorder (ADHD). Each item was based on a 4-point likert scale ranging from 0 (not at all) to 3 (very much). The overall score ranged from 0 to 78. The total score for Inattention and hyperactivity ranged from 0 to 27 and for oppositional ranged from 0 to 21. Mean Change was calculated as mean SNAP-IV score at Week 2 minus mean SNAP-IV score at Baseline.

2. Mean Change From Baseline in Swanson, Nolan and Pelham-Fourth Edition (SNAP-IV) Rating Scale (Parents) Score at Week 4 [Baseline and Week 4]

   Parents were asked to assess their children on a 26-item Chinese SNAP-IV questionnaire consisting of inattention (items 1-9; subscore range 0-27), hyperactivity (items 10-18; subscore range 0-27) and oppositional (19-26, subscore range 0-24) subscales used to assess the qualitative judgments in Attention Deficit Hyperactivity Disorder (ADHD). Each item was based on a 4-point likert scale ranging from 0 (not at all) to 3 (very much). The overall score ranged from 0 to 78. The total score for Inattention and hyperactivity ranged from 0 to 27 and for oppositional ranged from 0 to 21. Mean Change was calculated as mean SNAP-IV score at Week 4 minus mean SNAP-IV score at Baseline.

3. Mean Change From Baseline in Swanson, Nolan and Pelham-Fourth Edition (SNAP-IV) Rating Scale (Parents) Score at Week 8 [Baseline and Week 8]

   Parents were asked to assess their children on a 26-item Chinese SNAP-IV questionnaire consisting of inattention (items 1-9; subscore range 0-27), hyperactivity (items 10-18; subscore range 0-27) and oppositional (19-26, subscore range 0-24) subscales used to assess the qualitative judgments in Attention Deficit Hyperactivity Disorder (ADHD). Each item was based on a 4-point likert scale ranging from 0 (not at all) to 3 (very much). The overall score ranged from 0 to 78. The total score for Inattention and hyperactivity ranged from 0 to 27 and for oppositional ranged from 0 to 21. Mean Change was calculated as mean SNAP-IV score at Week 8 minus mean SNAP-IV score at Baseline.

4. Mean Change From Baseline in Chinese Health Questionnaire (CHQ) at Week 4 [Baseline and Week 4]

   The CHQ is a self administered screening instrument used to assess psychiatric morbidity in the Chinese community. It was derived from the General Health Questionnaire, and has been validated with satisfactory construct validity and applied in the survey of psychiatric morbidity in the community and in hospital settings. Four factors are included in the structure: somatic symptoms; anxiety and worrying; sleep problems; and depression and poor family relationships. It contains 12 items, with a maximum score of 12. CHQ scores indicated the severity of participants' psychological problems (0-2=normal; 3-4=minor; 5-6=moderate; and 7-12=severe psychological problems). Mean Change was calculated as mean CHQ score at Week 4 minus mean CHQ score at Baseline.

5. Mean Change From Baseline in Chinese Health Questionnaire (CHQ) at Week 8 [Baseline and Week 8]

   The CHQ is a self administered screening instrument used to assess psychiatric morbidity in the Chinese community. It was derived from the General Health Questionnaire, and has been validated with satisfactory construct validity and applied in the survey of psychiatric morbidity in the community and in hospital settings. Four factors are included in the structure: somatic symptoms; anxiety and worrying; sleep problems; and depression and poor family relationships. It contains 12 items, with a maximum score of 12. CHQ scores indicated the severity of participants' psychological problems (0-2=normal; 3-4=minor; 5-6=moderate; and 7-12=severe psychological problems). Mean Change was calculated as mean CHQ score at Week 8 minus mean CHQ score at Baseline.

Secondary Outcome Measures

1. Chinese Version of the Family Adaptation, Partnership, Growth, Affection, and Resolve (Family APGAR-C) Score [Baseline, Week 4 and 8]

   Parents of the participants were asked to assess the Family APGAR which is a 5-item questionnaire designed to assess the 5 dimensions of perceived family support: Adaptation, Partnership, Growth, Affection, and Resolve. Each item is rated on a 3-point scale ranging from 0 to 2 where 0=hardly ever, 1=some of the time and 2=almost always. The total score ranges from 0 to 10 with greater scores indicating greater family support.

2. Swanson, Nolan and Pelham-Fourth Edition (SNAP-IV) Rating Scale (Teachers) Score [Baseline, Week 2, 4 and 8]

   Teachers were asked to assess the children on a 26-item Chinese SNAP-IV questionnaire consisting of inattention (items 1-9; subscore range 0-27), hyperactivity (items 10-18; subscore range 0-27) and oppositional (19-26, subscore range 0-24) subscales used to assess the qualitative judgments in Attention Deficit Hyperactivity Disorder (ADHD). Each item was based on a 4-point likert scale ranging from 0 (not at all) to 3 (very much). The overall score ranged from 0 to 78. The total score for Inattention and hyperactivity ranged from 0 to 27 and for oppositional ranged from 0 to 21.

3. Social Adjustment Scale Score for Children and Adolescents (SAICA) [Baseline, Week 4 and Week 8]

   SAICA is a 77-item semi-structured interview scale designed for administration to school-aged children with age 6-18 years, or to their parents about their children. SAICA provides an evaluation of children's current functioning in the domains of school, spare time, peer relations, and home behaviors. Each item ranged on a 4-point likert scale ranging from 1 to 4 with a higher mean score indicating either poorer social function or a more severe social problem.

4. Clinical Global Impression-Severity (CGI-S) Score [Baseline, Week 2, 4 and 8]

   CGI-ADHD-S is a single item assessment of the global severity of ADHD symptoms in relation to the clinician's total experience after reviewing all the returned questionnaires and clinical assessment of participants' behavioral symptoms. Severity is rated on a 7-point scale ranging from 1 to 7 with 1=normal (not at all ill) and 7=most extremely ill.

5. Number of Participants With Clinical Global Impression-Improvement (CGI-I) Score [Baseline, Week 2, 4 and 8]

   CGI-I is a single item assessment of the global improvement of ADHD symptoms in relation to the clinician's total experience after reviewing all the returned questionnaires and clinical assessment of participants' behavioral symptoms. Improvement is rated on a 7-point scale (1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, and 7=very much worse).

6. Global Assessment of Satisfaction by Parents/Caregivers [Baseline, Week 2, 4 and 8]

   Parents/caregivers were asked to assess the satisfaction with respect to ADHD treatment on a 5-point scale ranging from 1 to 5 where 1=completely dissatisfied, 2=somewhat dissatisfied, 3=neutral, 4=somewhat satisfied, and 5=completely satisfied.

Other Outcome Measures

1. Global Assessment of Satisfaction by Participant [Baseline, Week 2, 4 and 8]

   Participants were asked to assess their satisfaction with respect to ADHD treatment on a 5-point scale ranging from 1 to 5 where 1=completely dissatisfied, 2=somewhat dissatisfied, 3=neutral, 4=somewhat satisfied and 5=completely satisfied.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 6 Years to 18 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Participants who are diagnosed with Attention Deficit Hyperactivity Disorder (ADHD) according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)

• Participants who have been treated with Immediate-release methyphenidate (IR-MPH) for at least 4 weeks before enrollment, but previous treatment is considered unsatisfactory due to 1 or more of the following reasons: lack of effectiveness, lack of tolerability or safety, lack of compliance, and/or other reasons

• Participants who are able to comply with the study visit schedule and whose parents/caregiver and community school teacher are willing and able to complete the protocol-specified assessments

• Participants who are still at school

• Participants who are treated with greater than equal to 10 milligram (mg) IR-MPH daily before enrollment

Exclusion Criteria:

• Participants who cannot understand or follow the instructions given in the study

• Participants with serious or unstable medical illness

• Participants who have clinically significant gastrointestinal problems, including narrowing of the gastrointestinal tract

• Participants who have glaucoma (increased pressure inside the eye that causes visual problems), an ongoing seizure disorders, or a psychotic disorder

• Participants who are hypersensitive to methylphenidate

• Participants who have any co-existing medical condition or are taking a concomitant medication that is likely to interfere with safe administration of methylphenidate

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

• Johnson & Johnson Taiwan Ltd

Investigators

• Study Director: Johnson & Johnson Taiwan, Ltd. Clinical Trial, Johnson & Johnson Taiwan Ltd

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Johnson & Johnson Taiwan Ltd
• ClinicalTrials.gov Identifier: NCT00758160
• Other Study ID Numbers: CR015331; CONCERTAATT4086; CCT-TWN-MA6
• First Posted: Sep 23, 2008
• Last Update Posted: Apr 8, 2014
• Last Verified: Mar 1, 2014

• Keywords provided by Johnson & Johnson Taiwan Ltd: Attention Deficit Disorder With Hyperactivity; Methylphenidate; Concerta
• Additional relevant MeSH terms: Hyperkinesis; Attention Deficit Disorder with Hyperactivity; Methylphenidate

Study Results

Participant Flow

Arm/Group Title	OROS MPH
Arm/Group Description	Participants received Osmotic Release Oral Delivery System (OROS) methylphenidate (MPH) 18 milligram (mg), 36 mg or 54 mg once daily for 8 weeks. Dose was adjusted for each participant based on clinical responses and/or side effects.
Period Title: Overall Study
STARTED	296
COMPLETED	230
NOT COMPLETED	66

Baseline Characteristics

Arm/Group Title	OROS MPH
Arm/Group Description	Participants received Osmotic Release Oral Delivery System (OROS) methylphenidate (MPH) 18 milligram (mg), 36 mg or 54 mg once daily for 8 weeks. Dose was adjusted for each participant based on clinical responses and/or side effects.
Overall Participants	296
Age (Years) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [Years]	9.5 (2.4)
Sex: Female, Male (Count of Participants)
Female	49 16.6%
Male	247 83.4%

Outcome Measures

1. Primary Outcome

Title	Mean Change From Baseline in Swanson, Nolan and Pelham-Fourth Edition (SNAP-IV) Rating Scale (Parents) Score at Week 2
Description	Parents were asked to assess their children on a 26-item Chinese SNAP-IV questionnaire consisting of inattention (items 1-9; subscore range 0-27), hyperactivity (items 10-18; subscore range 0-27) and oppositional (19-26, subscore range 0-24) subscales used to assess the qualitative judgments in Attention Deficit Hyperactivity Disorder (ADHD). Each item was based on a 4-point likert scale ranging from 0 (not at all) to 3 (very much). The overall score ranged from 0 to 78. The total score for Inattention and hyperactivity ranged from 0 to 27 and for oppositional ranged from 0 to 21. Mean Change was calculated as mean SNAP-IV score at Week 2 minus mean SNAP-IV score at Baseline.
Time Frame	Baseline and Week 2

Outcome Measure Data

Analysis Population Description

Intent-to-treat (ITT) analysis set included all participants who received OROS-MPH at least once and provided at least 1 post-baseline efficacy measurement. Here, 'n' included those participants who were evaluable for this measure at the specified time point.

Arm/Group Title	OROS MPH
Arm/Group Description	Participants received Osmotic Release Oral Delivery System (OROS) methylphenidate (MPH) 18 milligram (mg), 36 mg or 54 mg once daily for 8 weeks. Dose was adjusted for each participant based on clinical responses and/or side effects.
Measure Participants	296
Baseline: Inattention (n = 293)	1.7 (0.6)
Baseline: Hyperactivity (n = 293)	1.4 (0.7)
Baseline: Oppositional (n = 296)	1.3 (0.7)
Change at Week 2: Inattention (n = 293)	-0.4 (0.5)
Change at Week 2: Hyperactivity (n = 293)	-0.3 (0.5)
Change at Week 2: Oppositional (n = 296)	-0.3 (0.5)

2. Primary Outcome

Title	Mean Change From Baseline in Swanson, Nolan and Pelham-Fourth Edition (SNAP-IV) Rating Scale (Parents) Score at Week 4
Description	Parents were asked to assess their children on a 26-item Chinese SNAP-IV questionnaire consisting of inattention (items 1-9; subscore range 0-27), hyperactivity (items 10-18; subscore range 0-27) and oppositional (19-26, subscore range 0-24) subscales used to assess the qualitative judgments in Attention Deficit Hyperactivity Disorder (ADHD). Each item was based on a 4-point likert scale ranging from 0 (not at all) to 3 (very much). The overall score ranged from 0 to 78. The total score for Inattention and hyperactivity ranged from 0 to 27 and for oppositional ranged from 0 to 21. Mean Change was calculated as mean SNAP-IV score at Week 4 minus mean SNAP-IV score at Baseline.
Time Frame	Baseline and Week 4

Outcome Measure Data

Analysis Population Description

ITT analysis set included all participants who received OROS-MPH at least once and provided at least 1 post-baseline efficacy measurement. Here, 'n' included those participants who were evaluable for this measure at the specified time point.

Arm/Group Title	OROS MPH
Arm/Group Description	Participants received OROS MPH 18 mg, 36 mg or 54 mg once daily for 8 weeks. Dose was adjusted for each participant based on clinical responses and/or side effects.
Measure Participants	296
Change at Week 4: Inattention (n = 293)	-0.4 (0.6)
Change at Week 4: Hyperactivity (n = 293)	-0.3 (0.6)
Change at Week 4: Oppositional (n = 296)	-0.3 (0.6)

3. Primary Outcome

Title	Mean Change From Baseline in Swanson, Nolan and Pelham-Fourth Edition (SNAP-IV) Rating Scale (Parents) Score at Week 8
Description	Parents were asked to assess their children on a 26-item Chinese SNAP-IV questionnaire consisting of inattention (items 1-9; subscore range 0-27), hyperactivity (items 10-18; subscore range 0-27) and oppositional (19-26, subscore range 0-24) subscales used to assess the qualitative judgments in Attention Deficit Hyperactivity Disorder (ADHD). Each item was based on a 4-point likert scale ranging from 0 (not at all) to 3 (very much). The overall score ranged from 0 to 78. The total score for Inattention and hyperactivity ranged from 0 to 27 and for oppositional ranged from 0 to 21. Mean Change was calculated as mean SNAP-IV score at Week 8 minus mean SNAP-IV score at Baseline.
Time Frame	Baseline and Week 8

Outcome Measure Data

Analysis Population Description

ITT analysis set included all participants who received OROS-MPH at least once and provided at least 1 post-baseline efficacy measurement. Here, 'n' included those participants who were evaluable for this measure at the specified time point.

Arm/Group Title	OROS MPH
Arm/Group Description	Participants received OROS MPH 18 mg, 36 mg or 54 mg once daily for 8 weeks. Dose was adjusted for each participant based on clinical responses and/or side effects.
Measure Participants	296
Change at Week 8: Inattention (n = 293)	-0.5 (0.6)
Change at Week 8: Hyperactivity (n = 293)	-0.4 (0.6)
Change at Week 8: Oppositional (n = 296)	-0.4 (0.6)

4. Primary Outcome

Title	Mean Change From Baseline in Chinese Health Questionnaire (CHQ) at Week 4
Description	The CHQ is a self administered screening instrument used to assess psychiatric morbidity in the Chinese community. It was derived from the General Health Questionnaire, and has been validated with satisfactory construct validity and applied in the survey of psychiatric morbidity in the community and in hospital settings. Four factors are included in the structure: somatic symptoms; anxiety and worrying; sleep problems; and depression and poor family relationships. It contains 12 items, with a maximum score of 12. CHQ scores indicated the severity of participants' psychological problems (0-2=normal; 3-4=minor; 5-6=moderate; and 7-12=severe psychological problems). Mean Change was calculated as mean CHQ score at Week 4 minus mean CHQ score at Baseline.
Time Frame	Baseline and Week 4

Outcome Measure Data

Analysis Population Description

ITT analysis set included parents of all the participants who received OROS-MPH at least once and provided at least 1 post-baseline efficacy measurement. 'N' (number of participants analyzed) included those participants who were evaluable for this measure. 'n' included those participants who were evaluable for this measure at specified time point.

Arm/Group Title	OROS MPH
Arm/Group Description	Participants received OROS MPH 18 mg, 36 mg or 54 mg once daily for 8 weeks. Dose was adjusted for each participant based on clinical responses and/or side effects.
Measure Participants	275
Baseline: Mother Assessment (n = 275)	1.9 (0.6)
Baseline: Father Assessment (n = 216)	1.7 (0.4)
Change at Week 4: Mother Assessment (n = 275)	-0.1 (0.4)
Change at Week 4: Father Assessment (n = 216)	0 (0.3)

5. Primary Outcome

Title	Mean Change From Baseline in Chinese Health Questionnaire (CHQ) at Week 8
Description	The CHQ is a self administered screening instrument used to assess psychiatric morbidity in the Chinese community. It was derived from the General Health Questionnaire, and has been validated with satisfactory construct validity and applied in the survey of psychiatric morbidity in the community and in hospital settings. Four factors are included in the structure: somatic symptoms; anxiety and worrying; sleep problems; and depression and poor family relationships. It contains 12 items, with a maximum score of 12. CHQ scores indicated the severity of participants' psychological problems (0-2=normal; 3-4=minor; 5-6=moderate; and 7-12=severe psychological problems). Mean Change was calculated as mean CHQ score at Week 8 minus mean CHQ score at Baseline.
Time Frame	Baseline and Week 8

Outcome Measure Data

Analysis Population Description

ITT analysis set included parents of all the participants who received OROS-MPH at least once and provided at least 1 post-baseline efficacy measurement. 'N' (number of participants analyzed) included those participants who were evaluable for this measure. 'n' included those participants who were evaluable for this measure at specified time point.

Arm/Group Title	OROS MPH
Arm/Group Description	Participants received OROS MPH 18 mg, 36 mg or 54 mg once daily for 8 weeks. Dose was adjusted for each participant based on clinical responses and/or side effects.
Measure Participants	275
Change at Week 8: Mother Assessment (n = 275)	-0.1 (0.4)
Change at Week 8: Father Assessment (n = 216)	0 (0.4)

6. Secondary Outcome

Title	Chinese Version of the Family Adaptation, Partnership, Growth, Affection, and Resolve (Family APGAR-C) Score
Description	Parents of the participants were asked to assess the Family APGAR which is a 5-item questionnaire designed to assess the 5 dimensions of perceived family support: Adaptation, Partnership, Growth, Affection, and Resolve. Each item is rated on a 3-point scale ranging from 0 to 2 where 0=hardly ever, 1=some of the time and 2=almost always. The total score ranges from 0 to 10 with greater scores indicating greater family support.
Time Frame	Baseline, Week 4 and 8

Outcome Measure Data

Analysis Population Description

ITT analysis set included parents of all the participants who received OROS-MPH at least once and provided at least 1 post-baseline efficacy measurement. 'N' (number of participants analyzed) included those participants who were evaluable for this measure. 'n' included those participants who were evaluable for this measure at specified time point.

Arm/Group Title	OROS MPH
Arm/Group Description	Participants received OROS MPH 18 mg, 36 mg or 54 mg once daily for 8 weeks. Dose was adjusted for each participant based on clinical responses and/or side effects.
Measure Participants	281
Baseline: Mother Assessment (n = 275)	6.4 (2.9)
Baseline: Father Assessment (n = 216)	6.5 (2.5)
Week 4: Mother Assessment (n = 280)	6.6 (2.8)
Week 4: Father Assessment (n = 223)	6.7 (2.5)
Week 8: Mother Assessment (n = 281)	6.5 (3)
Week 8: Father Assessment (n = 226)	6.6 (2.7)

7. Secondary Outcome

Title	Swanson, Nolan and Pelham-Fourth Edition (SNAP-IV) Rating Scale (Teachers) Score
Description	Teachers were asked to assess the children on a 26-item Chinese SNAP-IV questionnaire consisting of inattention (items 1-9; subscore range 0-27), hyperactivity (items 10-18; subscore range 0-27) and oppositional (19-26, subscore range 0-24) subscales used to assess the qualitative judgments in Attention Deficit Hyperactivity Disorder (ADHD). Each item was based on a 4-point likert scale ranging from 0 (not at all) to 3 (very much). The overall score ranged from 0 to 78. The total score for Inattention and hyperactivity ranged from 0 to 27 and for oppositional ranged from 0 to 21.
Time Frame	Baseline, Week 2, 4 and 8

Outcome Measure Data

Analysis Population Description

ITT analysis set included of all the participants who received OROS-MPH at least once and provided at least 1 post-baseline efficacy measurement. 'N' (number of participants analyzed) included those participants who were evaluable for this measure. 'n' included those participants who were evaluable for this measure at specified time point.

Arm/Group Title	OROS MPH
Arm/Group Description	Participants received OROS MPH 18 mg, 36 mg or 54 mg once daily for 8 weeks. Dose was adjusted for each participant based on clinical responses and/or side effects.
Measure Participants	288
Baseline: Inattention (n = 281)	1.5 (0.7)
Baseline:Hyperactivity (n = 285)	1.1 (0.7)
Baseline: Oppositional (n = 283)	0.9 (0.7)
Week 2: Inattention (n = 286)	1.3 (0.7)
Week 2: Hyperactivity (n = 287)	0.9 (0.7)
Week 2: Oppositional (n = 286)	0.7 (0.7)
Week 4: Inattention (n = 287)	1.2 (0.6)
Week 4: Hyperactivity (n = 288)	0.9 (0.8)
Week 4: Oppositional (n = 287)	0.7 (0.7)
Week 8: Inattention (n = 287)	1.1 (0.6)
Week 8: Hyperactivity (n = 288)	0.8 (0.7)
Week 8: Oppositional (n = 287)	0.7 (0.7)

8. Secondary Outcome

Title	Social Adjustment Scale Score for Children and Adolescents (SAICA)
Description	SAICA is a 77-item semi-structured interview scale designed for administration to school-aged children with age 6-18 years, or to their parents about their children. SAICA provides an evaluation of children's current functioning in the domains of school, spare time, peer relations, and home behaviors. Each item ranged on a 4-point likert scale ranging from 1 to 4 with a higher mean score indicating either poorer social function or a more severe social problem.
Time Frame	Baseline, Week 4 and Week 8

Outcome Measure Data

Analysis Population Description

ITT analysis set included of all the participants who received OROS-MPH at least once and provided at least 1 post-baseline efficacy measurement. 'N' (number of participants analyzed) included those participants who were evaluable for this measure. 'n' included those participants who were evaluable for this measure at specified time point.

Arm/Group Title	OROS MPH
Arm/Group Description	Participants received OROS MPH 18 mg, 36 mg or 54 mg once daily for 8 weeks. Dose was adjusted for each participant based on clinical responses and/or side effects.
Measure Participants	165
Baseline (n = 151)	1.5 (0.7)
Week 4 (n = 160)	1.8 (0.3)
Week 8 (n = 165)	1.8 (0.3)

9. Secondary Outcome

Title	Clinical Global Impression-Severity (CGI-S) Score
Description	CGI-ADHD-S is a single item assessment of the global severity of ADHD symptoms in relation to the clinician's total experience after reviewing all the returned questionnaires and clinical assessment of participants' behavioral symptoms. Severity is rated on a 7-point scale ranging from 1 to 7 with 1=normal (not at all ill) and 7=most extremely ill.
Time Frame	Baseline, Week 2, 4 and 8

Outcome Measure Data

Analysis Population Description

ITT analysis set included of all the participants who received OROS-MPH at least once and provided at least 1 post-baseline efficacy measurement. 'N' (number of participants analyzed) included those participants who were evaluable for this measure. 'n' included those participants who were evaluable for this measure at specified time point.

Arm/Group Title	OROS MPH
Arm/Group Description	Participants received OROS MPH 18 mg, 36 mg or 54 mg once daily for 8 weeks. Dose was adjusted for each participant based on clinical responses and/or side effects.
Measure Participants	292
Baseline (n = 290)	4.3 (0.9)
Week 2 (n = 291)	3.5 (1.0)
Week 4 (n = 291)	3.1 (1.1)
Week 8 (n = 292)	3.0 (1.1)

10. Secondary Outcome

Title	Number of Participants With Clinical Global Impression-Improvement (CGI-I) Score
Description	CGI-I is a single item assessment of the global improvement of ADHD symptoms in relation to the clinician's total experience after reviewing all the returned questionnaires and clinical assessment of participants' behavioral symptoms. Improvement is rated on a 7-point scale (1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, and 7=very much worse).
Time Frame	Baseline, Week 2, 4 and 8

Outcome Measure Data

Analysis Population Description

ITT analysis set included of all the participants who received OROS-MPH at least once and provided at least 1 post-baseline efficacy measurement. 'N' (number of participants analyzed) included those participants who were evaluable for this measure. 'n' included those participants who were evaluable for this measure at specified time point.

Arm/Group Title	OROS MPH
Arm/Group Description	Participants received OROS MPH 18 mg, 36 mg or 54 mg once daily for 8 weeks. Dose was adjusted for each participant based on clinical responses and/or side effects.
Measure Participants	292
Week 2: Very much improved (n = 292)	4 1.4%
Week 2: Much improved (n = 292)	98 33.1%
Week 2: Minimally improved (n = 292)	126 42.6%
Week 2: No change (n = 292)	45 15.2%
Week 2: Minimally worse (n = 292)	16 5.4%
Week 2: Much worse (n = 292)	2 0.7%
Week 2: Very much worse (n = 292)	1 0.3%
Week 4: Very much improved (n = 262)	15 5.1%
Week 4: Much improved (n = 262)	111 37.5%
Week 4: Minimally improved (n = 262)	96 32.4%
Week 4: No change (n = 262)	27 9.1%
Week 4: Minimally worse (n = 262)	10 3.4%
Week 4: Much worse (n = 262)	3 1%
Week 4: Very much worse (n = 262)	0 0%
Week 8: Very much improved (n = 282)	16 5.4%
Week 8: Much improved (n = 282)	129 43.6%
Week 8: Minimally improved (n = 282)	91 30.7%
Week 8: No change (n = 282)	28 9.5%
Week 8: Minimally worse (n = 282)	13 4.4%
Week 8: Much worse (n = 282)	4 1.4%
Week 8: Very much worse (n = 282)	1 0.3%

11. Secondary Outcome

Title	Global Assessment of Satisfaction by Parents/Caregivers
Description	Parents/caregivers were asked to assess the satisfaction with respect to ADHD treatment on a 5-point scale ranging from 1 to 5 where 1=completely dissatisfied, 2=somewhat dissatisfied, 3=neutral, 4=somewhat satisfied, and 5=completely satisfied.
Time Frame	Baseline, Week 2, 4 and 8

Outcome Measure Data

Analysis Population Description

ITT analysis set included of all the participants who received OROS-MPH at least once and provided at least 1 post-baseline efficacy measurement. 'N' (number of participants analyzed) included those participants who were evaluable for this measure. 'n' included those participants who were evaluable for this measure at specified time point.

Arm/Group Title	OROS MPH
Arm/Group Description	Participants received OROS MPH 18 mg, 36 mg or 54 mg once daily for 8 weeks. Dose was adjusted for each participant based on clinical responses and/or side effects.
Measure Participants	291
Baseline (n = 290)	3.1 (0.9)
Week 2 (n = 291)	3.4 (0.8)
Week 4 (n = 291)	3.7 (0.8)
Week 8 (n = 291)	3.6 (0.9)

12. Other Pre-specified Outcome

Title	Global Assessment of Satisfaction by Participant
Description	Participants were asked to assess their satisfaction with respect to ADHD treatment on a 5-point scale ranging from 1 to 5 where 1=completely dissatisfied, 2=somewhat dissatisfied, 3=neutral, 4=somewhat satisfied and 5=completely satisfied.
Time Frame	Baseline, Week 2, 4 and 8

Outcome Measure Data

Analysis Population Description

ITT analysis set included of all the participants who received OROS-MPH at least once and provided at least 1 post-baseline efficacy measurement. 'N' (number of participants analyzed) included those participants who were evaluable for this measure. 'n' included those participants who were evaluable for this measure at specified time point.

Arm/Group Title	OROS MPH
Arm/Group Description	Participants received OROS MPH 18 mg, 36 mg or 54 mg once daily for 8 weeks. Dose was adjusted for each participant based on clinical responses and/or side effects.
Measure Participants	291
Baseline (n = 290)	3.2 (0.9)
Week 2 (n = 291)	3.5 (0.8)
Week 4 (n = 291)	3.7 (0.8)
Week 8 (n = 291)	3.6 (0.9)

Adverse Events

Adverse Event Reporting Description	Adverse events(AEs) data was reported for each visit as total data for AEs were not analyzed. In addition to the AEs reported in the below table, a category of AEs titled "Other" was reported as no dictionary was used and events under this category were not further specified. Total # affected by other AEs is minimum number of participants affected.
Arm/Group Title	OROS MPH-Baseline		OROS MPH-Week 2		OROS MPH-Week 4		OROS MPH-Week 8
Arm/Group Description	Participants received Osmotic Release Oral Delivery System (OROS) methylphenidate (MPH) 18 milligram (mg), 36 mg or 54 mg once daily for 8 weeks. Dose was adjusted for each participant based on clinical responses and/or side effects.		Participants received Osmotic Release Oral Delivery System (OROS) methylphenidate (MPH) 18 milligram (mg), 36 mg or 54 mg once daily for 8 weeks. Dose was adjusted for each participant based on clinical responses and/or side effects.		Participants received Osmotic Release Oral Delivery System (OROS) methylphenidate (MPH) 18 milligram (mg), 36 mg or 54 mg once daily for 8 weeks. Dose was adjusted for each participant based on clinical responses and/or side effects.		Participants received Osmotic Release Oral Delivery System (OROS) methylphenidate (MPH) 18 milligram (mg), 36 mg or 54 mg once daily for 8 weeks. Dose was adjusted for each participant based on clinical responses and/or side effects.
All Cause Mortality
	OROS MPH-Baseline		OROS MPH-Week 2		OROS MPH-Week 4		OROS MPH-Week 8
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	/ (NaN)		/ (NaN)		/ (NaN)		/ (NaN)
Serious Adverse Events
	OROS MPH-Baseline		OROS MPH-Week 2		OROS MPH-Week 4		OROS MPH-Week 8
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	0/296 (0%)		0/296 (0%)		0/296 (0%)		0/296 (0%)
Other (Not Including Serious) Adverse Events
	OROS MPH-Baseline		OROS MPH-Week 2		OROS MPH-Week 4		OROS MPH-Week 8
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	80/296 (27%)		100/296 (33.8%)		90/296 (30.4%)		95/296 (32.1%)
General disorders
Appetite decreased	80/296 (27%)		100/296 (33.8%)		90/296 (30.4%)		95/296 (32.1%)
Nausea	22/296 (7.4%)		22/296 (7.4%)		15/296 (5.1%)		15/296 (5.1%)
Insomnia	22/296 (7.4%)		35/296 (11.8%)		30/296 (10.1%)		25/296 (8.4%)
Headache	17/296 (5.7%)		14/296 (4.7%)		8/296 (2.7%)		7/296 (2.4%)
Dizziness	12/296 (4.1%)		10/296 (3.4%)		6/296 (2%)		9/296 (3%)
Somnolence	8/296 (2.7%)		4/296 (1.4%)		2/296 (0.7%)		1/296 (0.3%)
Abdominal pain	17/296 (5.7%)		20/296 (6.8%)		11/296 (3.7%)		12/296 (4.1%)
Stomachache	5/296 (1.7%)		4/296 (1.4%)		1/296 (0.3%)		1/296 (0.3%)
Other	26/296 (8.8%)		32/296 (10.8%)		25/296 (8.4%)		24/296 (8.1%)

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.